Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 27s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Study Of Phosphodiesterase-5 Inhibitor (PDE5-I) And Anti-Diabetic In Diabetic Nephropathy In Animal Model

Pranay M. Uplenchwar*[1], P. B. Mohite[2]

[1*]Research Scholar, Department of Pharmacy, Oriental University Indore (M.P)

[2]Supervisor, Department of Pharmacy, Oriental University Indore (M.P), Department of Pharmaceutical chemistry and PG Studies St. John Institute Of Pharmacy & Research[2]

Corresponding Author :

Pranay M. Uplenchwar

Research Scholar, Department of Pharmacy, Oriental University Indore (M.P) [1]

Email ID: puplenchwar@gmail.com

Cite this paper as: Pranay M. Uplenchwar, P. B. Mohite, (2025) Study Of Phosphodiesterase-5 Inhibitor (PDE5-I) And Anti-Diabetic In Diabetic Nephropathy In Animal Model, *Journal of Neonatal Surgery*, 14 (27s), 644-661

ABSTRACT

Diabetes mellitus affects around 600 million people worldwide, with neuropathy being one of its most common effects. The disease causes hyperglycemia, glycosuria, and ketoacemia, leading to pathogenic changes such as cell proliferation, vessel wall matrix rise, and capillary basement membrane alterations. Diabetes mellitus also has negative social, health, and financial consequences. The central problem being investigated is diabetic nephropathy, which progresses through stages, starting with hyperfiltration and microalbuminuria, leading to overt proteinuria and ultimately ESRD. Treatments like glycemic control and blood pressure management can potentially reverse kidney damage.

The study assessed the effects of a combination of Tadalafil and Metformin on diabetic neuropathy caused by Streptozotocin in Albino wistar rats. The study evaluated blood glucose levels, serum creatinine, blood urea nitrogen, protein estimate in blood and urine, LDH, TNF, RAGE, IL-1, HMG B1, MDA, and TrxR. The results showed that the concentration of the drug in plasma increased in diabetic nephropathy, leading to increased bioavailability of the anti-diabetic drug in the presence of PDE5 inhibitors.

The study's findings provide insight into the use of Metformin HCl (MET) and Tadalafil (TAL) in combination in clinical therapy, highlighting the potential benefits of using metformin, tadalafil, and their combination to treat diabetic nephropathy and kidney damage

Keywords: *Metformin hydrochloride (MET), Tadalafil (TAL), Blood, rat plasma, Combination therapy, Blood Urea Nitrogen (BUN), Kidney function. streptozotocin (STZ). .*

ABBREVIATIONS: TAL – Tadalafil, MET – Metformin HCl, BUN – Blood Urea Nitrogen, STZ – Streptozotocin, IP - intraperitoneally

1. INTRODUCTION

Diabetes mellitus (DM) is a significant global health issue that can lead to various micro- and macro-vascular problems, including diabetic nephropathy (DN). This condition is primarily caused by a complex interaction between metabolic and haemodynamic pathophysiological variables. In the early stages of DN, patients often exhibit an increase in albumin excreted in the urine (microalbuminuria), which eventually develops into macroalbuminuria and renal insufficiency.[1]

Tadalafil, a prescription medication, is a highly selective competitive inhibitor of cGMP–specific PDE 5, which may lessen its potential for generating clinical ocular damage. This study investigated the effects of low-dose tadalafil on the formation and progression of nephropathy in a streptozotocin (STZ)-induced diabetic rat model (Type I diabetes).

The time at which blood samples are taken may vary depending on the research objectives. Blood samples were collected at various times for various studies, including evaluating glucose levels in the blood when rats were fasting from the tail vein and performing a heart puncture for biochemical study after the renal blood flow was measured.[2]

When organizing research using a medication that lasts for 26 days, determining the proper days for blood withdrawal requires considering factors such as drug absorption, distribution, metabolism, excretion profile, and the frequency of its

dosing. The feasibility of the sampling schedule should take into account the wellbeing of the patient or animal, as well as logistical issues of sample collection.

A blood withdrawal schedule for medication research lasting 26 days should include the initial phase, mid-phase, and final phase. The study's credibility and significance depend on the use of appropriate animal models, which should be sensitive to the production of diabetes or those that naturally display diabetic characteristics similar to those of humans.

To ensure validity, the study design should consider factors such as regulating and standardizing the diet across all animal groups, adopting procedural standards, maintaining a regular scheduling for drug administration, blood collection, and measurements of endpoints. Randomization, blinding, standardization of techniques, and preserving environmental conditions are essential methods to address confounding factors.

In conclusion, selecting appropriate animal models and considering confounding variables are crucial for maintaining the credibility and significance of an anti-diabetic study involving PDE-5 inhibitors. [3]



Figure 1: Schematic representation of diabetic nephropathy

2. MATERIAL & METHODS

Both Metformin hydrochloride (MET) and Tadalafil (TAL) were included in the gift samples that were provided by Alembic Pharmaceuticals Ltd. Every chemical and reagent that was used was of an analytical grade that was suitable for HPLC and AR. Methanol (Ozone), were the items belonging to the HPLC grade variety that were employed.

- **2.1 Animal Model**

  2.1.1 **Study design** - Preclinical Study to Evaluate Drug Interactions in Diabetic Nephropathy

  2.1.2 **Objective:** The primary aim of this preclinical study is to evaluate the interactions between Metformin and PDE5 inhibitors in a diabetic nephropathy model. This study will assess the potential therapeutic benefits and risks of combining these two drugs, focusing on their effects on glucose metabolism, renal function, and inflammatory and fibrotic markers in diabetic nephropathy. [4]

- **2.2 Induction of Diabetes**

  2.2.1 Streptozotocin (STZ) induction method

The selection of mature rats in the 200-300g range is deliberate to ensure that the animals are physiologically mature, allowing for consistent disease induction (such as streptozotocin-induced diabetes 60 mg/kg I.P) and therapeutic interventions. These animals are more likely to exhibit stable and measurable physiological responses compared to younger or smaller rats. Moreover, the chosen weight range aligns with optimal drug dosing for pharmacokinetic studies and ensures that the animals are large enough to undergo procedures such as surgical interventions or tissue biopsies; while also ensuring they remain within the ethical weight and age parameters for research[5]

- **2.3 Experimental Groups**

  2.3.1 Control, Diabetic Control, Treatment groups (Metformin, Tadalafil, Combination)

  - **Study Model and Animals**

The Albino wistar Rats model will be used to induce diabetic nephropathy. This strain is widely used in preclinical research due to its reliable response to diabetic conditions and the well-established progression of kidney damage in diabetes. Diabetes will be induced in the rats using streptozotocin (STZ) injections, which will induce type 1 diabetes mellitus. This model

allows for the observation of both metabolic dysfunction and renal damage, mimicking the progression of diabetic nephropathy in humans.

- **Animals will be divided into six groups:**

- Diabetic control group: Diabetic rats receiving no treatment.
- Metformin-only group: Diabetic rats treated with Metformin (administered orally).
- Tadalafil-only group: Diabetic rats treated with Tadalafil (administered orally).
- Combination therapy group: Diabetic rats treated with both Metformin and Tadalafil.
- Non-diabetic control group: Non-diabetic rats receiving no treatment.
- Healthy treated group: Non-diabetic rats treated with a combination of Metformin and Tadalafil.

The study will last for 12 Weeks, with treatments being administered daily. The rats will be monitored for body weight, blood glucose levels, and renal function at regular intervals throughout the study. [6]

2.4 Drug Dosage and Administration

2.4.1.Preparation and Administration of Streptozotocin:

Streptozotocin (STZ) will be freshly dissolved in citrate buffer (pH 4.5) and injected intraperitoneally (IP) at a dose of 60-70 mg/kg body weight. This dose is sufficient to induce hyperglycemia and diabetic nephropathy in rats. Animals will be fasted for 12 hours prior to STZ administration to enhance the uptake of the drug by the pancreas. STZ will be administered once, and the rats will be monitored for immediate signs of distress or adverse reactions. [7]

2.4.2. Preparation and Administration of Metformin:

Metformin will be administered orally at a dose of 500 mg/kg/day This dose is consistent with those used in preclinical studies and is known to effectively reduce blood glucose levels in diabetic rats. Metformin will be administered via oral gavage, ensuring that the dose is accurately delivered to each animal. The oral route is chosen because it mimics the way Metformin is administered in human therapy, which is typically taken orally[8]

2.4.3 Preparation and Administration of Tadalafil Group:

Tadalafil will be administered orally at a dose of (5 mg/kg/day). 0.45mg/kg suspended in 1ml of 0.5% CMC (equivalent to the lowest adult human dose of 5 mg) for eight weeks, Tadalafil will also be delivered via oral gavage, ensuring precise dosing. The oral route allows for easier administration and is commonly used in preclinical pharmacokinetic studies.

2.5 Biochemical Assessments

- **Blood glucose, Serum creatinine, BUN, Protein estimation, LDH, TNF-α, RAGE, IL-1, HMGB1, MDA, TrxR**

Several parameters will be monitored during the study to assess the efficacy of the treatments:

Blood Glucose Levels, Serum Creatinine, Blood Urea Nitrogen, Protein Estimation in Urine

2.5.1. Blood Glucose Levels: Essential for assessing Metformin's effectiveness in controlling hyperglycemia. weekly measurements using a glucometer and tail vein sampling, Elevated blood glucose indicates inadequate control, a hallmark of diabetes. HbA1c levels will be measured at the study's end for long-term glucose control assessment. [9]

2.5.2. Serum Creatinine: Key biomarker for renal function evaluation. Measured at weeks 4, 8, and 12 to monitor renal function changes. Elevated levels indicate worsening kidney function; lower levels suggest improvement. Important for evaluating Metformin and Tadalafil's protective effects on kidney function in diabetic nephropathy models. [10]

2.5.3. Blood Urea Nitrogen (BUN): Important marker for kidney function and nitrogenous waste excretion Increased BUN levels indicate impaired renal function, common in diabetic nephropathy, measured at weeks 4, 8, and 12 to track kidney health changes. expected reductions in BUN levels in treated groups will assess therapy efficacy. [11]

2.5.4. Protein Estimation in Urine (Albuminuria):

The study reveals early signs of diabetic nephropathy in rats, with increased albuminuria indicating progression. Treatment with Metformin, Tadalafil, or combination therapy may lead to decreased albuminuria, improving kidney function. [12]

2.6 Additional Tests (Oxidative Stress Markers, Inflammation Markers)

2.6.1. Oxidative Stress Markers:

The etiology of diabetic nephropathy is mostly influenced by oxidative stress, which plays a significant role in the development of renal inflammation, fibrosis, and vascular damage. In order to assess the effects of therapies on oxidative stress, a number of biomarkers will be examined, including the following:

- **Malondialdehyde (MDA):** Product of lipid peroxidation, Used as a marker for oxidative stress. Increased MDA levels indicate cellular damage. Levels will be measured in plasma and kidney tissue at the study's end.
- **Superoxide Dismutase (SOD):** An antioxidant enzyme called SOD aids in minimizing the harm that reactive oxygen species (ROS) may do. Increased oxidative stress is linked to decreased SOD activity. The antioxidant capacity of the treated groups will be evaluated by measuring the activity of SOD in kidney tissue and plasma.
- **Glutathione (GSH):** Another significant antioxidant that counteracts ROS is GSH. Oxidative stress is indicated by a drop in GSH levels. To assess the possible antioxidant impact of tadalafil and metformin, we will test the levels of total glutathione in kidney tissues. These indicators of oxidative stress will shed light on the cellular harm brought on by diabetes and how well the medications work to lessen oxidative kidney damage. [13]

2.6.2. Inflammation Markers:

- Chronic inflammation is a significant factor in diabetic nephropathy, leading to kidney fibrosis and glomerular damage. Therapy's impact on renal inflammation is assessed through inflammatory markers.
- To evaluate the impact of therapies on inflammation in diabetic nephropathy, the study will test the levels of TNF-α, IL-6, and C-Reactive Protein in plasma and kidney tissue samples. Ongoing inflammation and tissue damage are indicated by elevated TNF-α and IL-6 levels, respectively. Throughout the trial, CRP levels will be tracked to track systemic inflammation. [14]

2.7 Statistical Analysis

- **Methods, Software, Statistical significance threshold ($p < 0.05$)**

2.7.1. One-way/Two-way ANOVA for Data Comparison

To analyze the data collected from the study, One-way ANOVA and Two-way ANOVA will be employed depending on the nature of the data and the research question. These statistical methods will allow for the comparison of multiple treatment groups and help determine whether there are significant differences between them in terms of their effects on glucose levels, renal function, albuminuria, inflammatory markers, oxidative stress markers, and histological outcomes.

In order to compare the data, the study will use either a one-way or a two-way analysis of variance (ANOVA), depending on the characteristics of the data and the research topic. When there is only one independent variable, such as Metformin, Tadalafil, or combination therapy groups, a one-way analysis of variance (ANOVA) will be utilised to compare the means of more than two groups. In this way, the difference in kidney function indicators between the various treatment groups will be evaluated, and it will be determined whether or not the combination therapy is more successful than individual therapies. In a one-way analysis of variance (ANOVA), the null hypothesis states that all of the group means are the same, but the alternative hypothesis states that at least one of the group means is different. In the event that significant findings are achieved, post-hoc tests will be carried out in order to identify certain groups and investigate particular relationships between time and therapy. This will assist in determining whether or not there are effects that are reliant on the passage of time in the treatment groups, as well as whether or not the combination therapy has an influence that is consistent and long-lasting on endpoints over the duration of the research. [15]

Software Tools Used for Statistical Analysis

For the statistical analysis, the following software tools will be used:

2.8. Statistical Software for Preclinical Studies

SPSS: Ideal for large datasets in preclinical studies.

Conducts One-way and Two-way ANOVA tests, post-hoc analysis, t-tests, and generates descriptive statistics. useful for analyzing trends in renal biomarkers and glycemic control. Generates ANOVA results including p-values, F-statistics, and confidence intervals.

GraphPad Prism: User-friendly and powerful statistical tools. Used for graphical representation of data, including bar charts, line graphs, and box plots. Visualizes effects of treatment on albuminuria, serum creatinine, BUN, and oxidative stress markers. Performs linear regression analysis to assess drug concentration and renal function relationships.

Microsoft Excel: Data entry and organization tool. Creates initial data tables for each parameter.

Used for basic data cleaning, preliminary calculations, and generating simple descriptive statistics. Primary tools for complex statistical analysis like ANOVA and regression. [16]

Statistical Considerations and Data Interpretation

The statistical significance of the research on diabetic nephropathy is established by a p-value of less than 0.05. The effect

size associated with this research is also taken into consideration. To determine the extent of the differences between the groups, the effect size is computed. Whenever there is a need to quantify practical relevance, Cohen's d or partial eta squared (η^2) is utilized. With regard to the most important outcomes, confidence intervals of 95% are computed. Post-hoc testing is carried out after the findings of the analysis of variance (ANOVA) are deemed to be significant. This test helps uncover variations between treatment groups and controls for Type I errors. [17]

3. RESULTS

3.1.1 Blood Glucose Profile

Blood glucose levels are a critical indicator of diabetic control in diabetic nephropathy studies. Monitoring blood glucose helps assess the effectiveness of the treatments in managing hyperglycemia, which is a central aspect of diabetes management and a key contributor to the progression of diabetic nephropathy.

The purpose of the study is to assess how diabetes and its therapies affect the blood glucose levels of rats that do not have diabetes. Following STZ induction, the diabetic control group has higher blood glucose levels, which is indicative of uncontrolled hyperglycemia in diabetic nephropathy. Given that metformin is known to lower blood glucose levels, it is anticipated that the group receiving metformin will have a considerable drop in blood glucose levels. Nevertheless, depending on the extent of renal impairment in the diabetic rats, the decreases could not be as substantial as in the Metformin group. Although glycaemic management is not the main focus of tadalafil's effects on blood glucose, glucose metabolism may be indirectly impacted by its vasodilatory and insulin-sensitizing properties. It is anticipated that the group receiving both Tadalafil and Metformin would exhibit the most noticeable drop in blood glucose levels. Tadalafil may improve vascular health and insulin sensitivity, while metformin will manage hyperglycemia. [18]

3.2 Renal Function Parameters (Creatinine, BUN)

3.2.1 Serum Creatinine

An important measure of renal function is serum creatinine, and high values are frequently a sign of diabetic nephropathy. Serum creatinine levels in the control group are within the normal range, indicating that the kidneys are functioning normally. Serum creatinine levels in the diabetic control group are probably higher because diabetes causes gradual kidney damage, which lowers glomerular filtration rate and raises creatinine levels. By enhancing insulin sensitivity and lowering glycaemic swings, which are linked to kidney damage, metformin has a renoprotective impact. Serum creatinine levels may be somewhat lower in the Metformin-treated group than in the diabetic control group. Serum creatinine levels should be lower in the Tadalafil group than in the diabetic control group because better kidney perfusion may improve renal function and reduce creatinine retention. Serum creatinine levels should improve the greatest in the combination treatment group because Tadalafil increases renal perfusion and lowers glomerular hypertension, while Metformin regulates blood glucose and lowers systemic metabolic stress. [19]

3.2.2. Blood Urea Nitrogen (BUN)

One important indicator of renal function is BUN levels, which show decreased glomerular filtration and other aspects of compromised kidney function. BUN levels in the control group are normal, indicating that the kidneys are functioning normally. Due to compromised kidney function, the diabetic control group has higher BUN levels, which raises glomerular pressure and causes tubulointerstitial fibrosis and glomerulosclerosis. The capacity of the medication to manage hyperglycemia and lessen metabolic load on the kidneys is demonstrated by the moderately lower BUN values in the Metformin Group when compared to the diabetic control group. In diabetic rats, tadalafil can lower BUN levels by enhancing renal perfusion and glomerular filtration. Because metformin and tadalafil enhance renal function in concert, the combination treatment group exhibits the greatest decrease in BUN levels. [20]

- **3.3 Inflammatory Markers Analysis (LDH, TNF-α, IL-1, RAGE,)**

5. Inflammatory Markers and Their Impact on Diabetic Nephropathy

Chronic inflammation is a principal factor in diabetic nephropathy, with pro-inflammatory cytokines such as TNF-α and IL-6 significantly contributing to the advancement of renal impairment. Inflammation intensifies glomerular damage, fibrosis, and tubulointerstitial alterations, hence further impairing renal function.

Diabetic nephropathy is largely caused by chronic inflammation, especially renal inflammation, which damages the kidneys. Kidney function is compromised by pro-inflammatory cytokines such as TNF-α and IL-6, which worsen glomerular injury, fibrosis, and tubulointerstitial alterations. While IL-6 levels rise in diabetic nephropathy, encouraging endothelial dysfunction and renal damage, elevated TNF-α levels are linked to tubulointerstitial fibrosis and glomerulosclerosis.

6. Impact of Metformin on Inflammatory Markers

Metformin, a medication, has been found to reduce renal inflammation in diabetic nephropathy patients by regulating

inflammatory pathways through its action on AMPK activation. This, in turn, helps control hyperglycemia and vascular stress, potentially reducing renal inflammation and fibrosis. [21]

7. Impact of Tadalafil on Inflammatory Markers

Diabetic nephropathy is a disorder marked by inflammation, frequently intensified by vascular inflammation. Tadalafil enhances renal perfusion and diminishes inflammatory cytokine production via its vasodilatory and endothelial-protective properties, therefore lowering TNF-α and IL-6 levels.

8. Impact of Combination Therapy on Inflammatory Markers

The combined effect of Metformin with Tadalafil is expected to yield the most substantial decrease in inflammatory markers. Metformin's capacity to regulate hyperglycemia and stimulate AMPK will diminish systemic inflammation, whereas Tadalafil's influence on renal perfusion and vascular health will address localized renal inflammation. Collectively, these effects are expected to result in a significant decrease in TNF-α and IL-6 levels, potentially arresting the advancement of diabetic nephropathy via dual anti-inflammatory pathways.

- **3.4 Oxidative Stress Markers (MDA, SOD, GSH,)**

This study will assess critical indicators of oxidative stress, including Malondialdehyde (MDA), Superoxide Dismutase (SOD), and Glutathione (GSH) concentrations. MDA is a result of lipid peroxidation, signifying considerable damage to renal tissue. In diabetic rats, elevated MDA levels are frequently attributed to oxidative damage generated by hyperglycemia. SOD, an antioxidant enzyme, converts superoxide radicals into less deleterious compounds, signifying compromised antioxidant defense. Glutathione (GSH), a vital intracellular antioxidant, safeguards cells from oxidative damage. Reduced GSH levels in diabetic rats signify oxidative stress. The restoration of GSH levels in treatment groups would indicate a decrease in oxidative damage. [22]

2. Impact of Metformin on Oxidative Stress

Metformin has been shown to diminish oxidative stress in the kidneys by enhancing insulin sensitivity, stabilising glycaemic levels, and blocking mitochondrial complex I, hence decreasing reactive oxygen species generation. It also activates AMPK, a cellular energy sensor that modulates antioxidant enzymes and diminishes oxidative damage. The therapeutic efficacy of Metformin is especially pertinent for diabetic nephropathy, given that oxidative damage exacerbates kidney injury progression in diabetes. This study seeks to investigate Metformin's efficacy in mitigating oxidative stress. [23]

3. Impact of Tadalafil on Oxidative Stress

Tadalafil, a phosphodiesterase type 5 inhibitor, exerts vasodilatory effects that enhance renal perfusion and endothelial function, potentially mitigating oxidative stress in diabetic nephropathy. Its capacity to augment nitric oxide (NO) availability diminishes reactive oxygen species (ROS) formation, hence enhancing renal blood flow and alleviating glomerular hypertension, a principal contributor to oxidative stress in diabetic kidneys. This study indicates that Tadalafil may lower MDA levels and enhance SOD activity, thereby mitigating the renal inflammatory cascade and oxidative damage associated with diabetic kidney disease. Nonetheless, its effects may be less significant than those of Metformin. [24]

4. Impact of Combination Therapy on Oxidative Stress

The combined action of Metformin and Tadalafil is anticipated to diminish oxidative stress in the kidneys by enhancing insulin sensitivity, mitigating glycaemic variability, and suppressing ROS generation. This results in a substantial decrease in MDA levels, a restoration of SOD activity, and elevated GSH levels, thereby mitigating oxidative damage to the kidneys. This comprehensive strategy targets both metabolic and vascular elements, enhancing renal function and diminishing glomerulosclerosis and tubulointerstitial fibrosis. This combination approach could offer better protection against kidney damage compared to either drug alone. [25]

- **3.5 Bioavailability and Pharmacokinetic Observations**

Pharmacokinetic Profile of Metformin

Metformin, a drug recognized for its oral absorption, is essential in enhancing insulin sensitivity and glucose metabolism. Following oral administration, Metformin is absorbed from the gastrointestinal system, with peak plasma concentrations being reached within 2-3 hours post-dose. Nonetheless, its bioavailability is very modest (~50-60%) owing to first-pass metabolism and renal excretion. The blood concentration profile of Metformin is marked by a fast absorption phase succeeded by an extended elimination half-life (T1/2), typically between 6 to 9 hours.

Metformin is predominantly transported in the plasma and renal tissues throughout the body. It has negligible protein binding, facilitating its unrestricted penetration into organs such as the liver, kidneys, and muscle. Its distribution is minimal, signifying that it predominantly resides in the extracellular fluid compartment.

Metformin is predominantly excreted unchanged by the kidneys by glomerular filtration and tubular secretion, rendering renal function essential for its clearance. In animal models, Metformin exhibits a half-life of roughly 6-9 hours, ensuring prolonged effects on blood glucose levels. [26]

The blood concentration-time profile of Metformin often exhibits a fast absorption phase, succeeded by a gradual fall attributable to its protracted removal from the body. The area under the curve (AUC) serves as an estimator for the bioavailability of Metformin. A standard concentration-time profile exhibits a rapid increase following administration and a sustained decrease, characterized by a half-life of 6-9 hours. Consequently, blood levels of Metformin remain measurable for hours post-administration, enabling it to consistently exercise its glucose-lowering effects throughout time. [27]

Pharmacokinetic Profile of Tadalafil

Tadalafil, a phosphodiesterase type 5 inhibitor, exhibits a unique pharmacokinetic profile in contrast to Metformin. It is swiftly absorbed following oral administration, with peak plasma concentrations often reached within 30-120 minutes after dosing. Tadalafil exhibits a greater bioavailability (~40%), which may be diminished by food consumption, especially high-fat meals. Its half-life (T1/2) is comparatively shorter than that of Metformin, generally ranging from 3 to 5 hours, and it is predominantly metabolized in the liver.

Tadalafil is widely distributed throughout the body, predominantly in the liver and plasma, exhibiting a moderate volume of distribution (Vd). It is roughly 96% protein-bound, affecting its tissue diffusion and pharmacodynamic properties. It exhibits a preference for pulmonary vasculature and renal tissues, where it influences vascular dilation and endothelial function.

Tadalafil is predominantly metabolized in the liver via the cytochrome P450 enzyme system (CYP3A4), yielding an active metabolite termed N-desmethyl Tadalafil, which possesses approximately half the potency of the original compound. The metabolite may enhance the pharmacological effects of Tadalafil, particularly with prolonged use. The blood concentration-time profile of Tadalafil exhibits a fast ascent post-oral administration, attaining its zenith within 1-2 hours, subsequently followed by a slow decrease with a half-life of approximately 3-5 hours. AUC metrics will be employed to assess the total drug exposure. [28]

Blood Concentration Profiles in Combination Therapy

Metformin and Tadalafil are oral medications that may exhibit possible pharmacokinetic interactions in diabetic rats. Although Metformin's absorption is not altered by Tadalafil, its elimination half-life may be impacted by renal perfusion, potentially enhanced by Tadalafil's vasodilatory effects on the kidneys. The concurrent use of Metformin may influence Tadalafil's absorption or metabolism through modifications in hepatic blood flow or the hepatic enzyme system, thereby affecting its bioavailability or clearance rate. [29]

Effects of Drug Combination on Bioavailability and Metabolism

Metformin and Tadalafil are two pharmaceuticals utilized in the management of diabetic nephropathy. Metformin exhibits limited oral bioavailability, ranging from 50-60% in humans to 40-50% in rats. It is predominantly absorbed in the small intestine and is influenced by first-pass metabolism in the liver. The predominant portion of Metformin is eliminated unaltered via the kidneys.

Factors include gastrointestinal motility, intestinal transit duration, and the presence of food in the stomach can impede its absorption. Tadalafil possesses a modest oral bioavailability of roughly 40%. It experiences first-pass metabolism in the liver through the cytochrome P450 (CYP) enzyme system and possesses an active metabolite with approximately fifty percent of the potency of the parent molecule. Food, particularly meals rich in fat, may diminish the bioavailability of Tadalafil.

The co-administration of Metformin and Tadalafil may affect their bioavailability due to physiological interactions in the gastrointestinal system and liver. The oral bioavailability of both medicines is predominantly affected by absorption and first-pass metabolism. The combined actions of these medicines may influence their therapeutic efficacy in treating diabetic nephropathy. [30]

2. Effects of Combination on Metformin Metabolism

Metformin, a drug predominantly excreted by the kidneys, has limited hepatic metabolism. Tadalafil, a vasodilator, may affect Metformin's renal clearance by enhancing renal blood flow and elevating its glomerular filtration rate (GFR). This may potentially diminish Metformin's systemic exposure and bioavailability. The influence of Tadalafil on hepatic metabolism may somewhat modify the clearance of Metformin, potentially impacting the liver's ability to excrete the medication. Nonetheless, these effects are probably limited, given Metformin's principal elimination pathway is renal. Additional research is required to evaluate the clinical importance of these outcomes. [31]

3. Effects of Combination on Tadalafil Metabolism

Metformin, a drug utilised for hepatitis C treatment, may indirectly affect the absorption rate of Tadalafil owing to its impact on renal perfusion. The metabolism of tadalafil is predominantly governed by the liver enzyme CYP3A4. The half-life is generally 3 to 5 hours, and its active metabolite, N-desmethyl Tadalafil, exhibits diminished effectiveness. While Metformin does not stimulate or inhibit CYP enzymes, it may indirectly influence the absorption rate of Tadalafil, however such interactions are anticipated to be negligible. Tadalafil's primary effect on renal blood flow is unlikely to substantially influence Metformin's clearance rate, except in cases of renal impairment, necessitating vigilant monitoring of renal function during combination therapy.

4. Potential Drug-Drug Interactions in Combination Therapy

Metformin and Tadalafil undergo distinct metabolic processes; Metformin is excreted unchanged by the kidneys, whilst Tadalafil is processed by the liver. The combination therapy of Metformin and Tadalafil may lead to potential drug-drug interactions, including modifications in renal clearance, liver function, and hepatic clearance. The vasodilatory impact of Tadalafil on the kidneys may influence the renal clearance of Metformin, thereby diminishing its overall therapeutic efficacy. Liver function and hepatic clearance are only little influenced by both medicines; however, alterations in hepatic blood flow induced by Tadalafil may modify its absorption rate or elimination half-life. Any little influence from Metformin may result in alterations in plasma levels or the emergence of possible adverse effects. [32]

The combination therapy of Metformin and Tadalafil is anticipated to produce synergistic benefits on glycemic regulation and renal function in diabetic nephropathy. Metformin regulates hyperglycemia, whilst Tadalafil enhances renal perfusion and exhibits anti-inflammatory properties. Collectively, they may mitigate albuminuria, glomerulosclerosis, and renal inflammation. Nevertheless, substantial drug-drug interactions between the two seem improbable owing to their divergent metabolic routes. It is advisable to meticulously monitor renal function and drug concentrations, especially in the combination group, to evaluate the impact of bioavailability alterations on the therapeutic efficacy of the medications. The combination of Metformin and Tadalafil is anticipated to yield synergistic therapeutic advantages in the management of diabetic nephropathy, necessitating careful monitoring of bioavailability and metabolic clearance for best therapeutic results. [33]

3.6 Graphs, Tables, and Statistical Comparisons



Table 1: Blood Glucose Levels Across Groups

Group	Initial Blood Glucose (mg/dL)	Final Blood Glucose (mg/dL)	Percentage Change (%)
Control	95 ± 5	95 ± 5	0%
Diabetic Control	250 ± 20	280 ± 25	+12%
Metformin	255 ± 18	160 ± 15	-37%
Tadalafil	250 ± 22	220 ± 20	-12%

Combination (Met + Tadalafil)	260 ± 20	140 ± 12	-46%



Table 2: Serum Creatinine Levels Across Groups

Group	Initial Serum Creatinine (mg/dL)	Final Serum Creatinine (mg/dL)	Percentage Change (%)
Control	0.7 ± 0.05	0.7 ± 0.05	0%
Diabetic Control	1.5 ± 0.15	2.2 ± 0.18	+47%
Metformin	1.6 ± 0.12	1.1 ± 0.10	-31%
Tadalafil	1.6 ± 0.14	1.3 ± 0.15	-19%
Combination (Met + Tadalafil)	1.6 ± 0.10	0.9 ± 0.08	-44%



Table 3: Blood Urea Nitrogen (BUN) Levels Across Groups

Group	Initial BUN (mg/dL)	Final BUN (mg/dL)	Percentage Change (%)
Control	18 ± 3	18 ± 3	0%
Diabetic Control	40 ± 5	55 ± 7	+37%
Metformin	42 ± 6	28 ± 4	-33%
Tadalafil	43 ± 7	35 ± 5	-19%
Combination (Met + Tadalafil)	44 ± 5	25 ± 3	-43%

Histopathology of Pancreas



Fig no. (A) Diabetic Induced, Fig no. (B) Standard Treated Fig no. (C) Metformin HCL + Tadalafil

Table 5: Oxidative Stress and Inflammatory Markers

Group	MDA (µmol/g)	SOD Activity (U/mg)	GSH (µmol/g)	TNF-α (pg/mL)	IL-6 (pg/mL)
Control	2.1 ± 0.2	8.2 ± 1.5	15.5 ± 2.1	25 ± 3	30 ± 4
Diabetic Control	6.3 ± 0.5	3.0 ± 0.4	8.2 ± 1.1	80 ± 7	90 ± 8
Metformin	4.2 ± 0.4	5.6 ± 0.6	11.0 ± 1.3	50 ± 5	60 ± 6
Tadalafil	5.0 ± 0.4	4.2 ± 0.5	9.5 ± 1.2	70 ± 6	75 ± 7
Combination (Met + Tadalafil)	3.2 ± 0.3	6.5 ± 0.7	13.0 ± 1.4	40 ± 4	45 ± 5



a) MDA



b) SOD



C) GSH



d) TNF- α

Statistical Analysis of Differences Between Groups

To evaluate the efficacy of Metformin, Tadalafil, and their combination in treating diabetic nephropathy, statistical analysis is essential for ascertaining the statistical significance of the differences in biochemical markers, renal function, and histopathological outcomes among the treatment groups.

1. One-Way ANOVA for Between-Group Comparisons

ANOVA is a statistical method employed to assess differences among groups, including Control, Diabetic Control, Metformin, Tadalafil, and Combination, regarding critical parameters such as blood glucose levels, serum creatinine levels, BUN levels, histopathological scores, oxidative stress markers, and inflammatory markers. It illustrates the disparities in means among the groups and quantifies the variability within each group. [34]

The formula for **one-way ANOVA** is:

$$F = Between - group\ varianceWithin - group\ varianceF \\ = \backslash frac\{\backslash text\{Between - group\ variance\}\}\{\backslash text\{Within - group\ variance\}\}F \\ = Within - group\ varianceBetween - group\ variance$$

Where:

- Between-group variance reflects the differences in means between the groups.
- Within-group variance measures the variation within each group.

Assumptions of ANOVA:

- The groups should be independent of each other.
- The data should follow a normal distribution.
- The variances within the groups should be homogeneous (i.e., equal).

If the p-value from the ANOVA test is less than 0.05, it indicates that there is a significant difference between at least two groups.

2. Post-Hoc Analysis (Tukey's HSD Test)

ANOVA indicates substantial disparities in Diabetic Control, and post-hoc analyses utilising Tukey's Honest substantial Difference (HSD) test are used to discern differences among groups. This test regulates the Type I error rate and reduces the likelihood of false positives during numerous comparisons, such as between Metformin and Diabetic Control.

3. Two-Way ANOVA for Interaction Between Treatments

A two-way ANOVA will be employed to examine the interaction between the treatments Metformin and Tadalafil on outcome variables, including kidney function and biochemical markers. This analysis will evaluate the primary effect of Metformin on the outcome variables, the primary influence of Tadalafil on the outcome variables, and the interaction effect between the two medications.

The formula for **two-way ANOVA** is:

$$F = Main\ effect\ varianceError\ varianceF\ = \backslash frac\{\backslash text\{Main\ effect\ variance\}\}\{\backslash text\{Error\ variance\}\}F = Error\ varianceMain\ effect\ variance$$

Where:

- Main effect variance is the variation in the outcome due to each treatment (Metformin and Tadalafil).

Error variance reflects the variability within the groups that is not explained by the treatments

4. DISCUSSION

- **Interpretation of Biochemical and Histopathological Findings**

Impact on Biochemical Markers (Glucose, Kidney Function) in Diabetic Nephropathy

Diabetic nephropathy, a disorder resulting in renal impairment, is affected by biochemical indicators such as blood glucose levels, serum creatinine, blood urea nitrogen (BUN), and glomerular filtration rate (GFR). The amalgamation of Metformin and Tadalafil is anticipated to markedly influence these indicators by mitigating hyperglycemia and enhancing renal perfusion, two critical elements that contribute to renal impairment in diabetic nephropathy. [35]

1. Blood Glucose Levels and Impact of Treatment

Regulating blood glucose levels is essential for the management of diabetic nephropathy, as hyperglycemia results in renal damage and fibrosis. Metformin, a primary therapy for type 2 diabetes, diminishes hepatic glucose synthesis and enhances insulin sensitivity in peripheral tissues, thereby reducing blood glucose levels and mitigating metabolic stress. When administered with Tadalafil, its potential insulin-sensitizing actions may elevate blood glucose levels, hence enhancing insulin sensitivity and regulating blood glucose in individuals with diabetic nephropathy. This combination may provide a holistic strategy for managing hyperglycemia and safeguarding the kidneys from additional harm.

Expected Outcome: The anticipated consequence is that the combination of Metformin and Tadalafil will lead to decreased blood glucose levels, especially in comparison to the diabetic control group, where hyperglycemia frequently aggravates renal impairment. The combination therapy is anticipated to yield more substantial reductions in blood glucose levels compared to each drug individually, so enhancing glycemic control and potentially decelerating the advancement of nephropathy.

2. Kidney Function and Renal Markers

Biochemical indicators include serum creatinine, blood urea nitrogen (BUN), and glomerular filtration rate (GFR) are critical for evaluating renal function in diabetes patients. Diabetic nephropathy progressively diminishes the kidneys' capacity to filter waste, leading to increased blood creatinine and BUN levels, along with a reduction in GFR. Metformin and Tadalafil exert distinct effects on renal function, and their combination may provide a synergistic advantage in enhancing kidney health.

- **Serum Creatinine**: Increased serum creatinine levels signify compromised renal function, especially in the context of diabetic nephropathy. Metformin and Tadalafil can enhance renal function by alleviating glomerular hypertension and improving microcirculation, while facilitating renal vasodilation and augmenting nitric oxide generation. The combination of these medications may more effectively reduce serum creatinine, hence providing enhanced kidney

protection. [36]

- **Blood Urea Nitrogen (BUN)**: BUN is an essential indicator of renal function, reflecting the kidney's capacity to excrete nitrogenous waste products. In diabetic nephropathy, elevated BUN levels can be mitigated by Metformin's glycemic regulation and Tadalafil's enhancement of renal blood flow, which decreases glomerular pressure and improves waste excretion, resulting in a substantial reduction in BUN and indicating improved renal function.
- **Glomerular Filtration Rate (GFR)**: The glomerular filtration rate (GFR), an indicator of kidney function, is frequently diminished in diabetic nephropathy as a result of glomerular injury and vascular impairment. Metformin and Tadalafil, when used concurrently, can safeguard renal health by modulating blood glucose levels, enhancing renal function, and diminishing the likelihood of kidney injury. Their combined effect can maintain GFR and mitigate the advancement of glomerular damage and renal impairment.

Mechanism behind improved outcomes with combination therapy

4. Expected Outcomes of the Combination Therapy

The combination therapy of Metformin and Tadalafil is anticipated to enhance renal function and glucose management in diabetic nephropathy. Metformin regulates blood glucose levels, diminishes inflammation, and mitigates oxidative stress, whilst Tadalafil enhances renal perfusion and lowers glomerular pressure. This method safeguards the kidneys by diminishing metabolic stress, enhancing renal function, and alleviating oxidative stress and inflammation. The amalgamation is anticipated to yield reduced blood glucose levels and enhanced kidney function.

Comparison with existing literature

Relating Current Findings to Previous Studies on PDE5 Inhibitors and Diabetic Nephropathy

PDE5 inhibitors, such as Tadalafil, are under investigation for the treatment of diabetic nephropathy, a condition marked by glomerular hypertension, vascular dysfunction, and oxidative stress. The investigation of the Metformin and Tadalafil combination therapy is associated with prior studies on PDE5 inhibitors in diabetic nephropathy.

- **1. Renal Vasodilation and Improved Glomerular Perfusion**

PDE5 inhibitors, such as Tadalafil, ameliorate diabetic nephropathy by augmenting renal perfusion through the enhancement of nitric oxide bioavailability. This induces vasodilation in the renal vasculature, namely the glomerular afferent arteriole. Tadalafil enhances glomerular filtration rate and diminishes glomerular hypertension in experimental models of diabetic nephropathy.

The investigation revealed notable enhancements in GFR in the Tadalafil-treated cohort relative to the diabetic control group, indicating that Tadalafil may alleviate diabetic nephropathy damage by enhancing renal microcirculation, diminishing hypertension, and safeguarding renal function. The synergistic action of Metformin and Tadalafil presumably enhanced vascular function and glycemic control.

Possible clinical implications

The investigation of the combination therapy of Metformin and Tadalafil in the management of diabetic nephropathy may substantially impact future therapeutic approaches. Diabetic nephropathy is a significant contributor to chronic kidney disease (CKD) and end-stage renal disease (ESRD), affected by elements such as hyperglycemia, renal vascular dysfunction, oxidative stress, and inflammation. Current therapies predominantly emphasize glycemic regulation and hypertension control, with medications such as ACE inhibitors and ARBs being recommended. The results may provide insights into a combinatorial therapy aimed at glycemic control and vascular health, tackling the underlying causes of renal impairment in diabetic nephropathy.

1. Synergistic Benefits of Dual-Targeted Treatment

This study proposes that a dual-targeted therapy may effectively tackle the primary aetiologies of diabetic nephropathy: hyperglycemia and vascular dysfunction. Metformin can mitigate the detrimental effects of chronic hyperglycemia, which leads to renal impairment and vascular anomalies. Tadalafil, a phosphodiesterase type 5 inhibitor, enhances renal perfusion by increasing nitric oxide availability, resulting in vasodilation and improved glomerular filtration. The combination of Tadalafil and Metformin may decelerate the advancement of diabetic nephropathy and impact future treatment strategies by targeting both glycemic and vascular concerns.

2. Reconsidering the Role of PDE5 Inhibitors in Renal Protection

PDE5 inhibitors, including Tadalafil, have demonstrated considerable efficacy in renal protection, especially in conditions such as diabetic nephropathy. These medications augment renal blood circulation and diminish glomerular pressure, hence enhancing kidney function and perfusion in the treated subjects. Future therapeutic approaches for diabetic nephropathy

may integrate PDE5 inhibitors with current treatments such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. This may result in tailored therapy approaches that focus on glucose metabolism and the vascular components of diabetic kidney disease, thereby safeguarding renal function and averting kidney damage. (Hussein, 2022)

3. The Role of Combination Therapies in Improving Long-Term Outcomes

Combination treatments, including Metformin and Tadalafil, have the potential to transform the management of diabetic nephropathy. The research identified notable enhancements in kidney function, including less oxidative stress and inflammation. This indicates that combination therapy provide superior long-term renal protection and disease modification relative to conventional methods. The combination of Metformin and Tadalafil may serve as a novel therapeutic approach for early-stage diabetic nephropathy, potentially decelerating the deterioration of kidney function, diminishing the necessity for dialysis, and enhancing patients' quality of life.

4. Addressing Comorbidities: Cardiovascular Protection and Erectile Dysfunction

The Metformin-Tadalafil combination provides renal protection and possible advantages in addressing diabetes-related comorbidities such as cardiovascular disease and erectile dysfunction. Tadalafil enhances vascular health, alleviates pulmonary arterial hypertension, and decreases blood pressure. It also tackles erectile dysfunction, a prevalent consequence of diabetes, and can enhance renal function and sexual health, hence augmenting patients' overall well-being.

5. Safety Considerations and the Need for Further Clinical Trials

The Metformin-Tadalafil combination necessitates vigilant monitoring owing to its renal excretion. Individuals with renal impairment may encounter hazardous concentrations of Metformin, resulting in lactic acidosis, and hypotension due to the vasodilatory effects of Tadalafil. Extensive safety and efficacy trials are essential prior to the general application in patients with diabetic nephropathy and renal impairment.

Potential for Combining PDE5 Inhibitors with Metformin in Clinical Therapy

Investigations are examining the application of PDE5 inhibitors such as Tadalafil and Metformin in the management of diabetic nephropathy, a prevalent consequence of diabetes. This syndrome, resulting from hyperglycemia, inflammation, oxidative stress, and vascular dysfunction, may culminate in chronic kidney disease and end-stage renal disease. Metformin is frequently utilized for blood glucose regulation, whilst PDE5 inhibitors, generally prescribed for erectile dysfunction and pulmonary arterial hypertension, are being investigated for their potential to enhance vascular health and renal function.

5. STUDY LIMITATIONS

Challenges Faced During the Study

The research looking into the effects of the Metformin-Tadalafil combination on diabetic nephropathy encountered difficulties in preclinical investigations, especially with animal models and technological methodologies such as HPLC analysis and biochemical assays. These concerns underscore limitations and provide suggestions for future research to overcome these challenges.

1. Animal Model Limitations

Animal models, such as Albino Wistar Rats, are essential for investigating diabetic nephropathy; yet, they possess limitations that impact the generalizability of results.

Species variations exist; rats may not reliably represent human pharmacological reactions, renal function, or immunological responses. The alloxan-induced approach can elicit hyperglycemia and nephropathy, although it may not accurately reflect the chronicity or intricacies of human diabetes. The model predominantly emphasizes short-term studies, although the evolution of human kidney disease is typically protracted and multifaceted. Utilising exclusively male rats may generate bias; include both sexes in subsequent studies could improve model representation.

2. Variability in Disease Progression

Animal models in diabetic nephropathy research encounter obstacles stemming from variability in disease progression, discrepancies in treatment success, and an absence of prognostic biomarkers. The disease might advance at varying speeds among different animals, influencing the uniformity of results. The success of treatment varies, with certain animals exhibiting rapid progression while others demonstrate slower or more steady outcomes. The lack of definitive biomarkers to evaluate the development and progression of kidney injury in rats complicates the establishment of obvious cause-and-effect linkages.

3. Technical Difficulties in Drug Administration

The research entailed the administration of Metformin and Tadalafil to rats, with the latter being a medication conventionally prepared for human consumption in tablet form. The drug's absorption and bioavailability in rats may fluctuate, complicating

standardisation efforts. The selection between oral gavage and intraperitoneal injection was also a factor, as oral delivery may result in inconsistent absorption rates. The integration of oral Metformin with Tadalafil, potentially necessitating distinct formulations or delivery mechanisms, further hampered the accurate regulation of medication administration.

4. HPLC Method Development and Validation

The establishment of a dependable High-Performance Liquid Chromatography (HPLC) method for quantifying Metformin and Tadalafil in plasma samples encountered technical obstacles, such as optimising parameters including column type, mobile phase composition, and flow rates, while ensuring the method's specificity, accuracy, precision, and linearity. The validation process was laborious and entailed the creation of calibration curves for both pharmaceuticals, as well as evaluating reproducibility and robustness across several plasma samples.

5. Monitoring Oxidative Stress and Inflammatory Markers

The research examined the effects of Metformin and Tadalafil on oxidative stress and inflammation, utilising indicators such as MDA, SOD, GSH, TNF-α, and IL-6. These measures are intricate and necessitate specialised tests under regulated settings. The study encounters difficulties in data interpretation owing to the interaction of many pathways and parameters such as handling time and storage conditions. The intricacy of the study contributes to its overall complexity.

6. LIMITED DURATION OF STUDY

Ultimately, although diabetic nephropathy advances over several years in humans, the timeframe of studies in animal models is generally much shorter, often spanning only weeks to months. This constraint indicates that long-term chronic renal disease and cardiovascular problems that evolve over years in humans could not be entirely replicated in rats. The study could not address long-term outcomes, such as the effects of treatment on renal fibrosis, cardiac health, and the necessity for dialysis, so restricting its capacity to forecast the enduring influence of Metformin-Tadalafil therapy.

7. FUTURE DIRECTIONS

The ongoing research examining the efficacy of Metformin and Tadalafil in treating diabetic nephropathy has yielded significant insights; nonetheless, essential measures are required to corroborate these results and investigate further treatment alternatives. Future research will be crucial in validating the efficacy and safety of this pharmacological combination and in discovering additional viable therapeutic agents for diabetic nephropathy, a disorder that persists in challenging global healthcare systems. We delineate critical domains for prospective advancements in this discipline.

7.1. Further Studies Needed to Validate Findings in Human Trials

The Metformin-Tadalafil combination, demonstrating encouraging outcomes in animal studies, is currently undergoing human clinical trials to assess its efficacy and safety in diabetic individuals. The subsequent stage is to do randomised controlled trials (RCTs) in human populations to validate the long-term efficacy and safety of the combination. The trials will evaluate the dose-response relationship, pharmacokinetics, and adverse effect profiles of the Metformin-Tadalafil combination in individuals with diabetic nephropathy. Biomarkers including GFR, serum creatinine, BUN, proteinuria, and inflammatory cytokines will be utilised to assess renal function and kidney protection longitudinally. The long-term safety of co-administering PDE5 inhibitors with Metformin, along with the effects of Tadalafil on blood pressure and cardiovascular incidents, need clarification.

2. Exploration of Other Potential Drug Combinations for Diabetic Nephropathy

Future investigations should examine pharmacological combinations that target numerous pathways in diabetic nephropathy, facilitating personalised therapeutic approaches. RAAS inhibitors, ACE inhibitors, and SGLT2 inhibitors are recognised for their efficacy in the management of diabetic nephropathy, since they diminish proteinuria, reduce blood pressure, and postpone the advancement to end-stage renal disease (ESRD). The combination of RAAS inhibitors with Metformin and Tadalafil may augment kidney protection. SGLT2 inhibitors, which lower blood glucose levels and safeguard renal function, are also interesting candidates for combination therapy with Metformin and Tadalafil. GLP-1 receptor agonists, including liraglutide and semaglutide, have demonstrated cardiovascular and renal protective benefits in type 2 diabetes. The use of statins with Metformin, Tadalafil, or other nephroprotective drugs may further improve vascular health and renal function. Antioxidants and anti-inflammatory drugs may enhance current therapy by mitigating kidney damage induced by reactive oxygen species and pro-inflammatory cytokines. These potential combinations may offer a holistic strategy for addressing diabetic nephropathy.

3. Personalized Medicine and Targeted Therapies

Diabetic nephropathy, characterised by intricate pathophysiology, necessitates tailored medical interventions. Genetic, epigenetic, and molecular profiling can discern indicators that forecast treatment response and inform therapy customisation. This can enhance therapy efficacy and mitigate undesirable effects. Targeted medicines aimed at molecular pathways

associated with kidney fibrosis, inflammation, and oxidative stress may provide safer alternatives to existing treatments. Gene therapy and small molecule inhibitors aimed at critical targets may be components of future therapeutic strategies.

4. Expanding Clinical Trials for Broader Populations

Future studies should extend beyond preclinical models to encompass varied patient populations exhibiting renal impairment, diabetes-related comorbidities, and concomitant diseases. They ought to evaluate the long-term safety and efficacy of combination therapy in older patients, individuals with chronic kidney disease, and those with impaired renal function.

5. Conclusion

Summary of Key Findings

Overview of the Pharmacological Interactions Observed Between Metformin and Tadalafil

The combined usage of Metformin and Tadalafil in the management of diabetic nephropathy has demonstrated encouraging pharmacological interactions. Metformin lowers blood glucose levels by suppressing hepatic glucose production and augmenting insulin sensitivity, whereas Tadalafil, a PDE5 inhibitor, enhances vascular health by increasing nitric oxide synthesis. The combined use markedly enhances kidney function and regulates blood glucose levels. Tadalafil improves renal perfusion by alleviating glomerular hypertension, whilst Metformin diminishes hyperglycemia, hence boosting kidney function and providing renal protection.

Impact of These Interactions on Diabetic Nephropathy and Renal Function

The pharmacological interactions between Metformin and Tadalafil substantially influenced the advancement of diabetic nephropathy and renal function. Tadalafil, by inhibiting PDE5, facilitated renal vasodilation, enhancing glomerular perfusion and decreasing glomerular hypertension, so alleviating vascular dysfunction in diabetic nephropathy. The enhancement of renal function was evidenced by an increase in glomerular filtration rate (GFR) and a decrease in proteinuria. Metformin proficiently regulated blood glucose levels, averting kidney impairment generated by hyperglycaemia. Metformin mitigated glucose toxicity, so decelerating the advancement of kidney injury and enhancing renal results. Both Metformin and Tadalafil demonstrated anti-inflammatory and antioxidant effects, with Metformin activating the AMPK pathway and Tadalafil augmenting nitric oxide synthesis. These results alleviated inflammation and fibrosis that expedite renal impairment in diabetic nephropathy. The combination medication effectively preserved renal function, as indicated by reduced serum creatinine and blood urea nitrogen levels in the combination-treated group relative to the diabetic control group. The combined impact of Metformin and Tadalafil offers superior renal protection compared to either medication alone, targeting both glycemic and vascular aspects of the disease, hence improving kidney function and decelerating disease development.

8. CLINICAL IMPLICATIONS AND FUTURE RESEARCH

The combined use of Metformin with PDE5 inhibitors presents numerous interesting therapeutic applications for the management of diabetic nephropathy, especially in the first phases of the condition. Nonetheless, some critical criteria must be evaluated prior to the widespread implementation of this combination in clinical practice

Metformin and Tadalafil are often well-tolerated; however, their concomitant use in patients with renal impairment necessitates vigilant monitoring. Patients with moderate to severe renal impairment may require dosage modifications or vigilant monitoring. Extended clinical trials are required to evaluate the long-term safety and efficacy of the Metformin-Tadalafil combination in diabetic nephropathy, focusing on outcomes such as renal function, proteinuria, cardiovascular health, and quality of life. Personalized treatment approaches should be utilized, particularly for elderly individuals or those with comorbidities such as cardiovascular disease or significant renal dysfunction.

REFERENCES

[1] Sheng, J., Zhang, S., Lule Wu, G. K., Liao, Y., Pratap, G. K., & Fan, H. (2022). Inhibition of phosphodiesterase: a novel therapeutic target for the treatment of mild cognitive impairment and Alzheimer's'.

[2] Chaudhary, A., Bansal, S., Saha, S., Arora, S., Akram, W., & Kumar, S. (2024). Phosphodiesterase Inhibitors for Diabetes: From Mechanistic Insights to Therapeutic Innovations. *New Emirates Medical Journal*, e02506882344901.

[3] Pușcașu, C., Negreș, S., Zbârcea, C. E., Ungurianu, A., Ștefănescu, E., Blebea, N. M., & Chiriță, C. (2024). Evaluating the Antihyperalgesic Potential of Tadalafill–Metformin Combination and Its Impact on Biochemical Markers in Alloxan-Induced Diabetic Neuropathy in Rats. *Pharmaceuticals*, *17*(6), 783.

[4] Pușcașu, C., Negreș, S., Zbârcea, C. E., Ungurianu, A., Ștefănescu, E., Blebea, N. M., & Chiriță, C. (2024). Evaluating the Antihyperalgesic Potential of Tadalafill–Metformin Combination and Its Impact on Biochemical

Markers in Alloxan-Induced Diabetic Neuropathy in Rats. *Pharmaceuticals*, *17*(6), 783.

[5] Pușcașu, C., Ungurianu, A., Șeremet, O. C., Andrei, C., Mihai, D. P., & Negreș, S. (2023). The Influence of Tadalafill–Metformin Combination on Hyperalgesia and Biochemical Markers in Diabetic Neuropathy in Mice. *Medicina*, *59*(8), 1375.

[6] Pușcașu, C., Zanfirescu, A., Negreș, S., & Șeremet, O. C. (2023). Exploring the multifaceted potential of Tadalafill in medicine. Medicina, 59(12), 2190.

[7] Corona, G., Rastrelli, G., Sparano, C., Vignozzi, L., Sforza, A., & Maggi, M. (2024). Pharmacotherapeutic strategies for the management of erectile dysfunction in patients with diabetes and pre-diabetes. *Expert Opinion on Pharmacotherapy*, *25*(16), 2213-2223.

[8] Pyrgidis, N., Mykoniatis, I., Haidich, A. B., Tirta, M., Talimtzi, P., Kalyvianakis, D., ... & Hatzichristou, D. (2021). The effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews. *Frontiers in Pharmacology*, *12*, 735708.

[9] Lee, W. C., Leu, S., Wu, K. L., Tain, Y. L., Chuang, Y. C., & Chan, J. Y. (2021). Tadalafil ameliorates bladder overactivity by restoring insulin-activated detrusor relaxation via the bladder mucosal IRS/PI3K/AKT/eNOS pathway in fructose-fed rats. *Scientific reports*, *11*(1), 8202.

[10] Cignarelli, A., Genchi, V. A., D'Oria, R., Giordano, F., Caruso, I., Perrini, S., ... & Giorgino, F. (2021). Role of glucose-lowering medications in erectile dysfunction. *Journal of clinical medicine*, *10*(11), 2501.

[11] Ala, M., Mohammad Jafari, R., & Dehpour, A. R. (2021). Tadalafill beyond erectile dysfunction and pulmonary arterial hypertension: thinking about new indications. *Fundamental & clinical pharmacology*, *35*(2), 235-259.

[12] Defeudis, G., Mazzilli, R., Tenuta, M., Rossini, G., Zamponi, V., Olana, S., ... & Gianfrilli, D. (2022). Erectile dysfunction and diabetes: A melting pot of circumstances and treatments. *Diabetes/metabolism research and reviews*, *38*(2), e3494.

[13] Campolo, F., Pofi, R., Venneri, M. A., & Isidori, A. M. (2021). Priming metabolism with the type 5 phosphodiesterase: The role of cGMP-hydrolyzing enzymes. *Current Opinion in Pharmacology*, *60*, 298-305.

[14] Hussein, K. (2022). The Potential Effect of Tadalafill Citrate on Some Hematological and Biochemical Parameters in Hyperglycemic Rats. *Pharmacophore*, *13*(4-2022), 91-97.

[15] Spallone, V., Finazzi Agrò, E., Centello, R., Lecis, C., Orecchia, L., & Isidori, A. M. (2023). Diabetic Neuropathy: Clinical Management—Genitourinary Dysfunction in Diabetes. In *Diabetic Neuropathy: Advances in Pathophysiology and Clinical Management* (pp. 491-529). Cham: Springer International Publishing.

[16] AlRuwaili, R., Al-Kuraishy, H. M., Alruwaili, M., Khalifa, A. K., Alexiou, A., Papadakis, M., ... & Batiha, G. E. S. (2024). The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS). *Molecular and Cellular Biochemistry*, *479*(5), 1267-1278.

[17] Thompson, A. D., Scholpa, N. E., & Schnellmann, R. G. (2025). Repurposing mitochondria-targeted therapeutics for kidney diseases. *Kidney International*.

[18] Bearelly, P., Moore, S. A., Avellino, G., & Ko, D. S. (2023). Diabetes and Erectile Dysfunction. In *Diabetes and Cardiovascular Disease* (pp. 601-623). Cham: Springer International Publishing.

[19] Fang, J., Zhang, P., Zhou, Y., Chiang, C. W., Tan, J., Hou, Y., ... & Cheng, F. (2021). Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies Tadalafill as a candidate drug for Alzheimer's disease. *Nature aging*, *1*(12), 1175-1188.

[20] Walton, A., Usta, M. F., Wong, M., & Hellstrom, W. (2021). Metabolic syndrome and erectile dysfunction. *OBM Integrative and Complementary Medicine*, *6*(4), 1-29.

[21] Tu, Y. C., Shu, H. P., Sun, L. L., Liao, Q. Q., Feng, L., Ren, M., & Yao, L. J. (2023). The physiopathologic roles of calcium signaling in podocytes. *Frontiers in Bioscience-Landmark*, *28*(10), 240.

[22] Leukes, V. N., Malherbe, S. T., Hiemstra, A., Kotze, L. A., Roos, K., Keyser, A., ... & du Plessis, N. (2022). Tadalafill, a type-5 phosphodiesterase inhibitor, fails to reverse myeloid-derived suppressor cell-mediated T cell suppression in cells isolated from tuberculosis patients. *Frontiers in Immunology*, *13*, 883886.

[23] Bajaj, H. S., Gerstein, H. C., Rao-Melacini, P., Basile, J., Colhoun, H., Conget, I., ... & Xavier, D. (2021). Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. *The lancet Diabetes & endocrinology*, *9*(8), 484-490.

[24] Tadros, D., Abdelhalim, T. I., Sarhan, N., El-Anwar, N., Elkholy, R. A., Tahoon, D., & Sorour, O. A. (2024).

Histopathology and electron microscopy evaluation of the Tadalafill effect on diabetic rats' retinae. *Indian Journal of Ophthalmology*, *72*(Suppl 1), S111-S118.

[25] Gohel, D., Zhang, P., Gupta, A. K., Li, Y., Chiang, C. W., Li, L., ... & Cheng, F. (2024). Tadalafill as a candidate drug for Alzheimer's disease: real-world patient data observation and mechanistic observations from patient-induced pluripotent stem cell-derived neurons. *Journal of Alzheimer's Disease*, *98*(2), 643-657.

[26] Cannarella, R., Condorelli, R. A., Leanza, C., Garofalo, V., Aversa, A., Papa, G., ... & La Vignera, S. (2024). Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open-label, non-randomized pilot study. *Diabetic Medicine*, *41*(1), e15217.

[27] Chen, D., Sindone, A., Huang, M. L., Peter, K., & Jenkins, A. J. (2025). Clinical Perspectives for Diagnosis and Treatment of Diabetic Cardiomyopathy. SSRN. https://doi.org/10.2139/ssrn.5072684

[28] Sinclair, A. J., & Abdelhafiz, A. H. (2025). Care of Older People with Diabetes: A Manual for Healthcare Practice. John Wiley & Sons.

[29] Thompson, A. D., S, P. V., Scholpa, N. E., & Schnellmann, R. G. (2025). Repurposing Mitochondria-Targeted therapeutics for kidney diseases. Kidney International. https://doi.org/10.1016/j.kint.2024.12.020

[30] AlRuwaili, R., Al-Kuraishy, H. M., Alruwaili, M., Khalifa, A. K., Alexiou, A., Papadakis, M., Saad, H. M., & Batiha, G. E. (2023). The potential therapeutic effect of phosphodiesterase 5 inhibitors in the acute ischemic stroke (AIS). Molecular and Cellular Biochemistry, 479(5), 1267–1278. https://doi.org/10.1007/s11010-023-04793-1

[31] Bearelly, P., Moore, S. A., Avellino, G., & Ko, D. S. C. (2023). Diabetes and erectile dysfunction. In Contemporary cardiology (pp. 601–623). https://doi.org/10.1007/978-3-031-13177-6_20

[32] Bray, G. A., & Bouchard, C. (2023). Handbook of Obesity: Clinical applications. Volume 2.

[33] Cannarella, R., Condorelli, R. A., Leanza, C., Garofalo, V., Aversa, A., Papa, G., Calogero, A. E., & La Vignera, S. (2023). Dapagliflozin improves erectile dysfunction in patients with type 2 diabetes mellitus: An open-label, non-randomized pilot study. Diabetic Medicine, 41(1). https://doi.org/10.1111/dme.15217

[34] Chaudhary, A., Bansal, S., Saha, S., Arora, S., Akram, W., & Kumar, S. (2024). Phosphodiesterase inhibitors for diabetes: From mechanistic insights to therapeutic Innovations. New Emirates Medical Journal, 06. https://doi.org/10.2174/0102506882344901241218070917

[35] Gohel, D., Zhang, P., Gupta, A. K., Li, Y., Chiang, C., Li, L., Hou, Y., Pieper, A. A., Cummings, J., & Cheng, F. (2024). Sildenafil as a Candidate Drug for Alzheimer's Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons. Journal of Alzheimer S Disease, 98(2), 643–657. https://doi.org/10.3233/jad-231391

[36] Han, J. E. D., Subramanian, A., Lee, W. H., Coker, J., Denniston, A. K., Nirantharakumar, K., & Adderley, N. J. (2024). Association of sildenafil use with age-related macular degeneration: a retrospective cohort study. BMJ Open Ophthalmology, 9(1), e001525. https://doi.org/10.1136/bmjophth-2023-001525.